The objective of cancer immunotherapy is to induce potent and long-lasting immune responses that allow the patients’ own immune system to destroy large tumor masses and prevent disease recurrence over time. Recent advances in immunotherapy resulted in promising clinical anti-tumor responses. Nevertheless, an important challenge remains the development of tumor resistance and disease progression during or after therapy. Therefore, the focus of this thesis lies on the improvement of an mRNAbased immunotherapy in order to prevent tumor regrowth after a period of initially successful therapeutic activity. In the first part, we demonstrated that immunotherapy efficacy largely depends on tumor location. Our findings showed that a highly suppressive TME of genital tract tumors could be abrogated by systemic use of cisplatin. Combination of the mRNA vaccine with cisplatin led to a complete and durable rejection of the majority of tumors. In the second part, we demonstrated that immunotherapy was associated with an increase in the number of cancer stem cells. We therefore investigated the disruption of IL-6/TGF-β pathways, thought to promote cancer stem cells with the blockade of three immune checkpoint molecules. This combination therapy significantly improved the therapeutic outcomes of the mRNA vaccine, leading to a complete tumor rejection in part of treated mice. In this thesis we demonstrate that there is still a need for the development of combination immunotherapies aiming at induction of potent tumorspecific immunity, boosting TILs and simultaneously targeting tumor escape mechanisms. Particularly for patients with advanced metastatic disease combinatorial immunotherapy may hold the greatest promise of success.
|Award date||16 Jan 2018|
|Place of Publication||Brussels|
|Publication status||Published - 2018|
- anti-tumor immunity